477 related articles for article (PubMed ID: 19747119)
1. Quinolones: action and resistance updated.
Drlica K; Hiasa H; Kerns R; Malik M; Mustaev A; Zhao X
Curr Top Med Chem; 2009; 9(11):981-98. PubMed ID: 19747119
[TBL] [Abstract][Full Text] [Related]
2. DNA gyrase, topoisomerase IV, and the 4-quinolones.
Drlica K; Zhao X
Microbiol Mol Biol Rev; 1997 Sep; 61(3):377-92. PubMed ID: 9293187
[TBL] [Abstract][Full Text] [Related]
3. DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage.
Chen CR; Malik M; Snyder M; Drlica K
J Mol Biol; 1996 May; 258(4):627-37. PubMed ID: 8636997
[TBL] [Abstract][Full Text] [Related]
4. Antibacterial action of quinolones: from target to network.
Cheng G; Hao H; Dai M; Liu Z; Yuan Z
Eur J Med Chem; 2013 Aug; 66():555-62. PubMed ID: 23528390
[TBL] [Abstract][Full Text] [Related]
5. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.
Pan XS; Fisher LM
Antimicrob Agents Chemother; 1997 Feb; 41(2):471-4. PubMed ID: 9021211
[TBL] [Abstract][Full Text] [Related]
6. Lethal fragmentation of bacterial chromosomes mediated by DNA gyrase and quinolones.
Malik M; Zhao X; Drlica K
Mol Microbiol; 2006 Aug; 61(3):810-25. PubMed ID: 16803589
[TBL] [Abstract][Full Text] [Related]
7. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae.
Okumura R; Hirata T; Onodera Y; Hoshino K; Otani T; Yamamoto T
J Antimicrob Chemother; 2008 Jul; 62(1):98-104. PubMed ID: 18390884
[TBL] [Abstract][Full Text] [Related]
8. Amino acid substitutions of quinolone resistance determining regions in GyrA and ParC associated with quinolone resistance in Acinetobacter baumannii and Acinetobacter genomic species 13TU.
Liu YH; Kuo SC; Lee YT; Chang IC; Yang SP; Chen TL; Fung CP
J Microbiol Immunol Infect; 2012 Apr; 45(2):108-12. PubMed ID: 22153765
[TBL] [Abstract][Full Text] [Related]
9. Probing the differential interactions of quinazolinedione PD 0305970 and quinolones with gyrase and topoisomerase IV.
Pan XS; Gould KA; Fisher LM
Antimicrob Agents Chemother; 2009 Sep; 53(9):3822-31. PubMed ID: 19564360
[TBL] [Abstract][Full Text] [Related]
10. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.
Pan XS; Fisher LM
Antimicrob Agents Chemother; 1998 Nov; 42(11):2810-6. PubMed ID: 9797208
[TBL] [Abstract][Full Text] [Related]
11. Fluoroquinolones: action and resistance.
Drlica K; Malik M
Curr Top Med Chem; 2003; 3(3):249-82. PubMed ID: 12570763
[TBL] [Abstract][Full Text] [Related]
12. A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitors.
Hsiung Y; Elsea SH; Osheroff N; Nitiss JL
J Biol Chem; 1995 Sep; 270(35):20359-64. PubMed ID: 7657608
[TBL] [Abstract][Full Text] [Related]
13. Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding.
Mustaev A; Malik M; Zhao X; Kurepina N; Luan G; Oppegard LM; Hiasa H; Marks KR; Kerns RJ; Berger JM; Drlica K
J Biol Chem; 2014 May; 289(18):12300-12. PubMed ID: 24497635
[TBL] [Abstract][Full Text] [Related]
14. Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance.
Aldred KJ; McPherson SA; Wang P; Kerns RJ; Graves DE; Turnbough CL; Osheroff N
Biochemistry; 2012 Jan; 51(1):370-81. PubMed ID: 22126453
[TBL] [Abstract][Full Text] [Related]
15. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
Cheng J; Thanassi JA; Thoma CL; Bradbury BJ; Deshpande M; Pucci MJ
Antimicrob Agents Chemother; 2007 Jul; 51(7):2445-53. PubMed ID: 17502409
[TBL] [Abstract][Full Text] [Related]
16. Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.
Pan XS; Yague G; Fisher LM
Antimicrob Agents Chemother; 2001 Nov; 45(11):3140-7. PubMed ID: 11600369
[TBL] [Abstract][Full Text] [Related]
17. Isolation and quantitation of topoisomerase complexes accumulated on Escherichia coli chromosomal DNA.
Aedo S; Tse-Dinh YC
Antimicrob Agents Chemother; 2012 Nov; 56(11):5458-64. PubMed ID: 22869559
[TBL] [Abstract][Full Text] [Related]
18. Frequency of DNA gyrase and topoisomerase IV mutations and plasmid-mediated quinolone resistance genes among Escherichia coli and Klebsiella pneumoniae isolated from urinary tract infections in Azerbaijan, Iran.
Azargun R; Soroush Barhaghi MH; Samadi Kafil H; Ahangar Oskouee M; Sadeghi V; Memar MY; Ghotaslou R
J Glob Antimicrob Resist; 2019 Jun; 17():39-43. PubMed ID: 30445211
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of drug resistance: quinolone resistance.
Hooper DC; Jacoby GA
Ann N Y Acad Sci; 2015 Sep; 1354(1):12-31. PubMed ID: 26190223
[TBL] [Abstract][Full Text] [Related]
20. The determination of gyrA and parC mutations and the prevalence of plasmid-mediated quinolone resistance genes in carbapenem resistant Klebsiella pneumonia ST11 and ST76 strains isolated from patients in Heilongjiang Province, China.
Zeng L; Zhang J; Li C; Fu Y; Zhao Y; Wang Y; Zhao J; Guo Y; Zhang X
Infect Genet Evol; 2020 Aug; 82():104319. PubMed ID: 32278145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
